Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00430248 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Oral Febuxostat in Participants With Gout
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,269
- Enrollment target
NCT00430248: Completed Phase 3 study, sponsored by Takeda.
NCT00430248 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 2,269 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (194% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00430248, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,269 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and safety of febuxostat, once Daily (QD), to allopurinol in subjects with hyperuricemia and gout.
Primary Outcome
The percentage of subjects whose serum urate level was \<6.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate value was collected.
Interventions
- DRUG Allopurinol
- DRUG Febuxostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,269 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
What the finished NCT00430248 record still lists
NCT00430248 is an interventional study that assigns participants to a tested intervention. Its 2,269 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (194% higher).
The record links to 0 conditions, and to 2 interventions - of which Allopurinol is the first listed.
NCT00430248 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00430248 about?
NCT00430248 is a clinical study titled "Efficacy and Safety of Oral Febuxostat in Participants With Gout". The purpose of this study is to compare the efficacy and safety of febuxostat, once Daily (QD), to allopurinol in subjects with hyperuricemia and gout.
What is the current status of trial NCT00430248?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,269 participants. The study started on 2007-02. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00430248?
The interventions under investigation include: Allopurinol (DRUG), Febuxostat (DRUG).
Who is sponsoring clinical trial NCT00430248?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00430248's enrollment target sits among peer trials
2,269 94th of 2000 higher than 1,907 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03968393 · 2,270 participants · Phase 4
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
- NCT04889872 · 2,250 participants · NA
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
- NCT06805513 · 2,250 participants · Phase 3
Actual Use Trial of Tadalafil 5 mg
- NCT05530343 · 2,298 participants · NA
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia